Biotech Holdings Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Holdings

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: dodger2 who wrote (56)	5/7/1997 9:03:00 PM
From: tommysdad	of 224

It's actually Troglitazone (aka Rezulin) and is the first of a new class of NIDDM drugs, the thiazolidinones (TZD's), that interact with PPAR-gamma. Discovered by Sankyo (Japan) but marketed in the States by Warner-Lambert (just got FDA approval in March/April). There are a number of second- and third-generation TZD's in various stages of pre-clinical or clinical development by a number of companies (AHP, Glaxo, etc.). There is another class of drugs, the rexinoids, which complement the TZD's {and act through another set of receptors called the RXRs}, which was recently discovered. The relevance to Biotech Holdings is this: is DIAB-II acting through either of these pathways? Or is it something new? I don't think the company knows at this point -- there is no indication that they have the technology to determine the answer.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next